Experimental investigation of the critical Reynolds number for bubbly two-phase flow

The critical Reynolds number for dispersed bubbly two-phase flows, gas in liquid, was experimentally investigated. In this experiment, the gas was air and the liquid was water. Water flowed upward through a vertical, translucent pipe, and air was introduced into the water prior to the test section by means of a basswood microbubbler. Dye was injected into the water to indicate when the flow transitioned from laminar to turbulent. Mixtures with gas volume fractions up to 10% were tested, and the Reynolds numbers for which the flow transitioned from laminar to turbulent were recorded. The data showed that the critical Reynolds number fell to roughly one-half of its original single-phase liquid value once the gas volume fractions exceeded 0.1%. These results indicate that the presence of even small amounts of bubbles causes pre-mature transition to turbulence

Unveiling the molecular environment of the ring nebula RCW 78

We present a study of the ionized, neutral atomic, and molecular gas associated with the ring nebula RCW 78 around the WR star HD 117688 (= WR 55). We based our study on CO observations carried out with the SEST and NANTEN telescopes. We report the detection of molecular gas with velocities in the range -56 to -33 km/s. The CO emission is mainly connected to the western section, with a total molecular mass of 1.3 x 10^5 solar masses. The analysis of the HI gas distribution reveals the HI envelope of the molecular cloud, while the radio continuum emission shows a ring-like structure, which is the radio counterpart of the optical nebula. The gas distribution is compatible with the western section of RCW 78 having originated in the photodissociation and ionization of the molecular gas by HD 117688, and with the action of the stellar winds of the WR star. A number of infrared point sources classified as YSO candidates showed that stellar formation activity is present in the molecular gas linked to the nebula. The fact that the expansion of the bubble have triggered star formation in this region can not be discarded.Comment: 15 pages, 11 Postscript figures, to be published in A&

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council